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Aim: To determine the rate, etiological agents, antibiotic susceptibilities, and empirical treatment options of etiological agents of invasive
device-associated hospital infections (IDAHIs) in the medical intensive care unit of a university hospital.
Materials and methods: Between February 2007 and December 2009, 780 IDAHI cases were evaluated in 1650 patients.
Results: Ventilator associated pneumonia, catheter-associated urinary tract infection, and central venous catheter-associated blood
stream infection were observed in 415, 242, and 143 IDAHI cases, respectively. The most frequently isolated etiological agents were
Acinetobacter spp. in ventilator-associated pneumonia, coagulase-negative staphylococci (CoNS) in central venous catheter-associated
blood stream infection, and Candida spp. and E. coli in catheter-associated urinary tract infection.
Conclusion: In our study, oxacillin resistance in coagulase-positive S. aureus and CoNS was high. Glycopeptides and linezolid should
be considered as treatment options. Resistance of enteric bacteria is defined high against cephalosporin, aminoglycoside, and quinolone.
Carbapenems can be considered in the empirical treatment of enteric bacterial infections. Colistin can be given in the treatment of
resistant Acinetobacter infections as a therapeutic option. Since antifungal resistance is low, fluconazole should be the first drug of choice
in the treatment of candidal infections.
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1. Introduction
Hospital infections, which are the most important cause
of morbidity and mortality in intensive care units (ICUs),
increase the duration of hospitalization and treatment
costs. Severity of underlying diseases, wide spectrum
antibiotic use, and frequency of invasive procedures
cause increased infection rates in ICUs. The majority of
these infections can be prevented by routine surveillance
programs and infection control measures. Evaluation of
invasive device-associated hospital infections (IDAHI),
mainly for calculation of ICU infection rates, is a more
useful method to compare the rates both within and
between hospitals. Therefore, infections can be compared
in patients who are confronted with the same risk.
This study was performed in the medical intensive care
unit (MICU) of our hospital to define factors in IDAHI
rates and antibiotic susceptibility of causative factors.
2. Materials and methods
Adult patients who were 16 or older and hospitalized
* Correspondence: vbosnak@hotmail.com

for longer than 48 h in the 28-bed MICU at the Medical
Faculty Hospital of Gaziantep University between February
2007 and December 2009 were enrolled in the study. The
medical records of 1650 patients (447 patients in 2007, 618
patients in 2008, and 585 patients in 2009) were reviewed
retrospectively for hospital infections related to invasive
device, causative microorganisms, and their susceptibility
to antibiotics.
The Medical Faculty Hospital of Gaziantep University
has 934 patient beds and is located in southeast
Turkey. The MICU is located on the second floor and
it provides intensive care unit service for patients who
are hospitalized, and it has a total capacity of 28 patient
beds with 16 isolation rooms. The staff is composed of a
constant academic member, research assistants, and a
nurse for every 3 beds during the day and night.
Invasive device-related infection surveillance is
performed with patient- and laboratory-based active
surveillance methods by an infection control physician
and infection control nurse. Information about patients is
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recorded on the patient monitoring form during their stay
in the MICU by visits every day during the week. Invasive
device-related infections are diagnosed according to
definition criteria given by the Centers for Disease Control
and Prevention (CDC). As hospital infections are based
on CDC and calculations of infection rates are based on
recommendations of the National Nosocomial Infection
Surveillance system (NNIS), invasive device use rates are
calculated by the “invasive device use days/hospitalization
days” formula, and IDAHI rates are calculated by the
“device associated hospital infection number in 1-year
time/invasive device use days × 1000” formula (1). Device
use rates and invasive device related infection rates are
compared with data from the National Healthcare Safety
Network (NHSN).
Peripheral blood cultures and blood cultures from the
catheters, which were taken from patients followed up at
ICU-IMs with the preliminary diagnosis of invasive devicerelated hospital infections (IDRHIs) and transferred under
sterile conditions, were monitored under BacT/Alert
(Biomerieux, France) automated blood culture system, and
cultures that produced positive signals underwent further
processes. They were passed over eosin-methylene-blue
(EMB) and sheep blood agar plaques. Then 3–4-cm tip
portions of urinary and central venous catheters (CVCs)
were implanted semiquantitatively into blood agar and
EMB agar under sterile conditions by the Maki method.
A VITEK 2 (Biomerieux, France) fully automated device
for identification and antibiogram was used for bacterial
identification and antibiogram. Extended spectrum beta

lactamase production (ESBL) in E. coli and Klebsiella
species, and oxacillin resistance in Staphylococcus species
were evaluated by ESBL test panels of VITEK 2.
SPSS for Windows version 11.5 was used for data
evaluation. Two independent rates were compared by Z test.
Statistical level of significance was accepted as P ≤ 0.05.
3. Results
Out of 1650 patients, 780 IDAHI cases were defined.
Ventilator-associated pneumonia (VAP), catheterassociated urinary tract infection (CA-UTI), and central
venous catheter-associated circulation infection (CVCABSI) were observed in 415, 242, and 143 IDAHI cases,
respectively. Number of patients internalized into the
MICU, disease days, and hospital infection incidence are
shown in Table 1.
In the 3-year time period, the 3 most frequently isolated
etiological agents were Acinetobacter spp., Pseudomonas
spp., and coagulase-positive staphylococci (CPS) in VAP;
Acinetobacter spp., coagulase-negative staphylococci
(CoNS), and Enterococcus spp. in CVCA-BSI; and E. coli,
Candida spp., and Enterococcus spp. in CA-UTI. Isolated
agents in VAP, CVCA-BSI, and CA-UTI are shown in
Table 2.
While oxacillin resistance according to the years was
94%, 84%, and 82% for CPS and 100%, 100%, and 84% for
CoNS, vancomycin resistance according to the years was
36%, 29%, and 6% for Enterococcus spp.
Among the Acinetobacter spp. isolated from VAP,
amikacin resistance in 2008 and imipenem resistance

Table 1. Rates of device-associated hospital infections.
2007

2008

2009

Patient days

6093

7275

6369

Days on ventilator

3484

3846

3483

Rate of ventilator use

0.57

0.52

0.55

VAP rate

38.1

37.7

39.7

CVC days

2093

3342

4145

Rate of CVC use

0.47

0.46

0.65

CVCA-BSI rate

15.8

8.3

11.9

Urinary catheter days

5295

6680

6029

Rate of urinary catheter use

0.86

0.91

0.95

UCA-UTI rate

13.4

12.1

14.9

VAP: Ventilator-associated pneumonia; CVC: Central venous catheter; CVCA-BSI:
CVC associated blood stream infection; UCA-UTI: Urinary catheter-associated urinary
tract infection.
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Table 2. Distribution of isolated microorganisms according to infection types, n(%).

Microorganisms

VAP

CVCA-BSI

UCA-UTI

2007

2008

2009

2007

2008

2009

2007

2008

2009

Acinetobacter spp.

30
(26.3)

71
(52.6)

91
(63.2)

9
(25)

11
(21.2)

5
(7.2)

4
(5.5)

10
(11.4)

Pseudomonas spp.

37
(32.5)

19
(14.1)

29
(20.1)

9
(19.6)
5

1
(1.9)

7
(10.1)

6
(8.2)

5
(5.7)

Klebsiella spp.

5
(4.4)

10
(14.1)

4
(2.7)

(10.8)
3
(6.5)

3
(8.3)
2
(5.5)

4
(7.7)

2
(2.9)

9
(12.3)

6
(6.8)

E. coli

4
(3.5)

5
(3.7)

4
(2.7)

1
(2.2)

2
(5.5)

0
(0)

26
(37.7)

14
(19.2)

10
(11.4)

PC (+) staphylococci

26
(22.9)

14
(10.4)

7
(4.8)

6
(13)

14
(10.4)

4
(7.7)

0
(0)

0
(0)

1
(1.1)

PC (–) staphylococci

1
(0.8)

3
(2.2)

1
(0.7)

8
(17.4)

4
(11.1)

18
(34.6)

0
(0)

2
(2.7)

0
(0)

-

-

-

5
(10.8)

3
(8.3)

9
(17.3)

18
(26.1)

25
(34.2)

43
(48.9)

Enterococcus spp.

0
(0)

0
(0)

1
(0.7)

8
(17.4)

3
(8.3)

3
(5.8)

9
(13)

11
(15.1)

13
(14.8)

Enterobacter spp.

1
(0.8)

0
(0)

1
(0.7)

0
(0)

2
(5.5)

2
(3.8)

1
(1.4)

0
(0)

0
(0)

in 2007, 2008, and 2009 were statistically significantly
increased in comparisons (P < 0.05). There was a statistically
significant increase in antibiotic resistance comparisons
of cefoperazone–sulbactam, ceftazidime, trimethoprim–
sulfamethoxazole, and cefepime between 2007 and 2009
as well as 2008 and 2009 (P < 0.05). Resistance increases in
these antibiotics are shown in the Figure.
Among the Acinetobacter spp. isolated in CVCABSI, there was no statistically significant difference in
antibiotic resistance comparisons of amikacin, piperacillin
tazobactam, cefepime, ceftazidime, or imipenem in 2007,
2008, or 2009 (P > 0.05). Among E. coli, which was the
most commonly isolated agent in CA-UTI, there was no
statistically significant difference in antibiotic resistance
comparisons of amikacin, ciprofloxacin, piperacillin–
tazobactam, cefepime, ceftazidime, or imipenem in 2007,
2008, or 2009 (P > 0.05).
It was observed that E. coli, one of the invasive devicerelated hospital infection agents, secreted ESBL at 77.4% in
2007, 71.4% in 2008, and 64.3% in 2009. However, isolated
Klebsiella spp. secreted ESBL in 40% in 2007, 71.4% in
2008, and 28.6% in 2009.
There was no statistically significant difference between
isolated ESBL positive E. coli numbers in comparisons of
2007, 2008, and 2009 (P > 0.05). There was a statistically

100.0
90.0
Antibiotic resistance (%)

Candida spp.

80.0
70.0
60.0
50.0
40.0
CFP/SUL
TMP/SMP
IMP
CTZ
CEFP

30.0
20.0
10.0
0

2007

2008

2009

Figure. Antibiotic resistances according to years in Acinetobacter
spp. in VAP.
CFP/SUL: Cefoperazone/Sulbactam, TMP/SMP: Trimethoprim/
Sulfamethoxazole, IMP: Imipenem, CTZ: Ceftazidime, CEFP:
Cefepime

significant increase in 2008 in isolated EBSL positive
Klebsiella spp. when 2008 and 2009 were compared (P <
0.05).
Among isolated CPS S. aureus, oxacillin resistance was
94% in 2007, 84% in 2008, and 82% in 2009. Among CoNS,
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oxacillin resistance was 100% in 2007 and 2008, whereas it
was 84% in 2009. Among the Enterococcus spp. isolated,
vancomycin resistance demonstrated a decreasing trend of
29% in 2007, 36% in 2008, and 6% in 2009. There was no
statistically significant difference in oxacillin resistance in
2007, 2008, or 2009 between isolated CPS and CoNS (P
> 0.05). There was no statistically significant difference in
vancomycin resistance of Enterococcus spp. in comparisons
of 2007, 2008, and 2009 (P > 0.05).
While amikacin resistance of Acinetobacter spp. in
VAP cases was 40%–69% (P < 0.05), cefoperazone–
sulbactam resistance was 3.3% in 2007 and 12.6% in 2008,
but significantly increased to 73.6% in 2009 (P < 0.05).
While tigecycline resistance was not evaluated in 2007, it
was 5.6% and 5.5% in 2008 and 2009, respectively.
In our study, while imipenem, piperacillin–tazobactam,
and cefepime resistance of Acinetobacter spp. isolated in
2009 from CVCA-BSI were high, it was not statistically
significant when compared with that in 2007 and 2008 (P
> 0.05). While there was no resistance to cefoperazone–
sulbactam in 2007 and 2008, it was 54.4% in 2009. As
oxacillin resistance was over 80% in all 3 years for S. aureus,
it was 100% in 2007 and 2008 and 75% in 2009 for CoNS.
Gentamicin resistance of E. coli isolated from CAUTI in our study was over 50% in all 3 years, whereas
ciprofloxacin resistance was 40%–78.5% and imipenem
resistance was 0%–19.2%. However, there was no
statistically significant increase in antibiotic resistance of
E. coli in 2007, 2008, or 2009 (P > 0.05).
4. Discussion
Nosocomial colonization of resistant pathogens and
infection development are inevitable in ICUs, because of
the many invasive procedures being performed, crossinfections due to close contact between patients and
healthcare personnel, and wide-spectrum antibiotic use in
these units.
When our data are compared with those of NHSN,
mechanical ventilation (MV) use rates were between
the 50th and 75th percentiles in 2007, 2008, and 2009,
and VAP rates were over the 90th percentile. While our
ventilator use rates are close to the mean values, high
rates of VAP may be due to intubation under emergency
conditions, incompliance with control recommendations
for infections while cleaning up the mechanical ventilator
circuits, elongation of ventilator support duration,
underlying diseases of patients, quality of healthcare
service personnel, and, most importantly, lack of hand
hygiene.
CVC use rate was at the 25th percentile (low catheter
use rate) in 2007 and 2008 and at the 90th percentile
in 2009. However, the CVCA-BSI rate was over the
90th percentile in all 3 years. Urinary catheter use rates
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were over the 75th percentile in 2007 and over the 90th
percentile in 2008 and 2009, whereas infection rates were
over the 90th percentile, namely very high, in all 3 years.
This indicated that high rates of urinary catheter use may
have increased the infection rate, and so refraining from
unnecessary use of urinary catheters may have decreased
the UCA-UTI rate.
When our IDAHI rates are compared with those of
NHSN results, the high rates showed that efforts towards
infection prevention should be increased. Moreover,
factors affecting the results may be long durations of
patients in MICUs or nurse and healthcare personnel
problems, which are encountered sometime in ICUs.
The results indicate that more comprehensive studies are
required to be conducted on this issue.
Dizbay et al. (2) reported from their study including
ICUs of the Medical Faculty of Gazi University in Turkey
that VAP rates were 38 and 34, whereas CA-UTI rates were
9 and 7.3 and CVCA-BSI rates were 15.3 and 7.4 in 2006
and 2007, respectively.
Candevir et al. (3) reported in their study including
ICUs of the Medical Faculty of Çukurova University in
Turkey that the VAP rate was 21, whereas CA-UTI rate
was 10 and CVCA-BSI rate was 9 between 2006 and 2009.
Invasive device-associated hospital infection rates in the
MICUs of our university were similar to these rates.
Device-associated hospital infection rates in the ICUs
of 4 hospitals in Peru in 2005 and 2006 were compared
with the results of NHSN. While VAP, CVCA-BSI, and
CA-ITU rates in Peru were 31.3, 7.7, and 5.1, the results
of NHSN were 3.6, 2.4, and 3.4, respectively. These results
were over the 90th percentile, when compared with
the NHSN data. The high results in Peru indicated that
efficient surveillance is required and serious studies should
be performed in compliance with providing hand hygiene
(4).
In a 3-year study conducted in 10 ICUs of 9 hospitals
in Colombia, rates of VAP, CVCA-BSI, and CA-ITU were
10.0, 11.3, and 4.3, respectively. When these results were
compared with 2004 data from NNIS, they were over the
90th percentile, and so it was concluded that more effective
infection control measures are required in Colombia (5).
In a study performed in 13 ICUs of 12 hospitals in
Turkey, which are members of the International Infection
Control Consortium (INICC), total rates of VAP, CVCABSI, and CA-ITU were calculated as 26.5, 17.6, and 8.3,
respectively (6). When these results were compared with
NNIS data, they were over the 90th percentile, and were
similar to our results.
In our study, the most frequently isolated
microorganisms in VAP were Acinetobacter spp., which
have been reported to have gained increased importance.
They may cause small-scale epidemics in ICUs by infecting
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immunocompromised and debilitated patients (7). In our
study, the reason for frequently encountering Acinetobacter
spp. may be similar, but additionally host factors (DM,
malignancy, and previous antibiotic use history), lack
of qualified personnel, and poor compliance with hand
hygiene are the other reasons.
CVCs are indispensable devices applied for monitoring
and treatment of patients in ICUs. It has been reported that
1 out of 20 applied CVCs caused CVCA-BSI, and more
than 400,000 BSIs have been encountered annually (8). The
most frequently encountered factors in CVCA-BSI were PC
(–) staphylococci, S. aureus, aerobic gram-negative bacilli,
and Candida spp. This order differs according to hospitals
and units. In the last decade, it has been demonstrated
that PC (–) staphylococci rates increased 10% in BSIs and
the majority of sepsis cases associated with catheters are
caused by PC (–) staphylococcus epidemics (9,10).
It has been demonstrated that CVC use increases
development of candidemia 6-fold, whereas inappropriate
fluconazole use increases development of candidemia
9-fold (11). In our study, CVC use was increased in 2009
when compared with the other years, and thus it is thought
that one of the reasons for increased Candida infections
might be increased use of CVCs.
The relationship between application of urinary
catheters, duration of catheterization, and CA-UTI
development has been demonstrated in many studies (12).
In a study performed by Laupland et al. (13), the most
frequently isolated agents in decreasing order were E. coli
(23%), Candida spp. (20%), and Enterococcus spp. (15%).
In our study, the high rates of Candida infections might
have been due to long duration of urinary catheterization
and wide-spectrum antibiotics used in the majority of
patients.
Inappropriate antibiotic use is quite common all
over the world. As a result of frequent and inappropriate
antibiotic use in ICUs, infections with multiple drug
resistant microorganisms develop and difficulties are
experienced in treating them. Especially the use of
third generation cephalosporin, fluoroquinolone, and
carbapenem derivatives plays an important role in the
development of infections, which are caused by resistant
microorganisms (14). In general, antibiotic resistance
rates in ICUs in Turkey are higher than those in ICUs
at NNIS hospitals in the USA (15). According to NNIS
reports, methicillin-resistant S. aureus isolates (89.2% vs.
48.1%), ceftriaxone-resistant Enterobacter spp. (48.2%
vs. 48.1%), and fluoroquinolone-resistant P. aeruginosa
(51.1% vs. 29.1%) have been defined. High resistance rates
are observed against all wide-spectrum antibiotics, which
have been used commonly in ICUs (16).
Resistance rates of infectious agents causing devicerelated hospital infections were reported as 89.2% for S.

aureus against methicillin, 87.1% for Acinetobacter spp.
against piperacillin–tazobactam, 48.2% for Enterobacter
spp. against ceftriaxone and 52% against piperacillin–
tazobactam, 51.1% for P. aeruginosa against ciprofloxacin
and 38.7% against imipenem, and 1.9% for Enterococcus
spp. against vancomycin in a multicenter study performed
in Turkey (6).
In Peru, infectious agents for device-associated hospital
infections in ICUs of 4 hospitals, which were INICC
members, were 73.5% methicillin-resistant S. aureus,
62% ceftazidime-resistant Pseudomonas aeruginosa,
36.1% imipenem-resistant Pseudomonas spp., and 40.8%
ceftazidime-resistant Enterobacter spp. (4).
According to these results, high antibiotic resistance
of microorganisms may be related to initiation of
inappropriate antibiotics and unnecessary antibiotic use
with long stay of patients in MV, which may cause elongated
ICU durations, and so colonized microorganisms become
pathogens and gain resistance to the antibiotics given.
When surveillance data for 2007–2009 were evaluated,
our IDAHI rates were high. Moreover, in prevention of
infections in patients, decreasing IDAHI rates like VAP,
CVCA-BSI, and CA-UTI becomes a fatal and cardinal issue.
Our main aim is to protect the patient from infections, and
so increasing compliance, complete attendance of training
programs, and strict checking of compliance should be
ensured. Moreover, rational policies for antibiotic use
should be constituted. Increased vancomycin consumption
is known to have a significant role in observations of
vancomycin-resistant enterococci and staphylococci with
decreased vancomycin susceptibility.
Surveillance data for 2007–2009 have guided us
as to which empirical treatments should be used in
invasive device-associated nosocomial infections in
ICUs. The most commonly isolated microorganism in
VAP is Acinetobacter spp. The preferred antibiotics may
be amikacin, cefoperazone–sulbactam, and colistin.
Although these antibiotics can be used for empirical
treatments due to their low resistance rates, because of
their rapidly developed resistance profile antibiograms
should be studied. Although Acinetobacter spp. have been
observed to be susceptible to tigecycline, it should not be
the first line drug because of its low penetration rate into
the lung parenchyma.
The most commonly isolated agents in CVCA-BSIs are
Acinetobacter spp., and PC (–) staphylococci are second.
Because of high oxacillin resistance, glycopeptides can
be preferred empirically in the presence of gram-positive
bacteria. However, as infection rates with staphylococci are
decreased, antibiotherapy based on culture/antibiogram is
more appropriate than empirical treatment.
The most common agent for CA-UTI is E. coli. In
empirical treatments in E. coli infections, resistance
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to ciprofloxacin, amikacin, and cefepime should be
considered.
5. Conclusions
In order to decrease high invasive device-associated hospital
infection rates, continuation of surveillance should be
provided, unnecessary MV and catheter use should be
avoided, and patients should be detached from ventilators and
catheters removed as soon as possible. Increasing compliance
to standard isolation measures, qualified personnel training,
and hand hygiene should be considered.
In our study, oxacillin resistance in CPS and CoNS was
high. Methicillin resistance should be considered while
empirical treatment for staphylococcus infection is planned
in the Intensive Care Unit of Internal Medicine (ICU-

IM). Glycopeptides and linezolid should be considered as
treatment options. Resistance of enteric bacteria is high
against cephalosporin, aminoglycoside, and quinolone.
Carbapenems can be considered in the empirical treatment
of enteric bacterial infections. Resistance of Acinetobacter
spp. to amikacin and cefoperazone is increased over
time. Colistin can be given in the treatment of resistant
Acinetobacter infections as a therapeutic option. Since
antifungal resistance is low, fluconazole should be the first
drug of choice in treatment of candidal infections.
Data obtained by routine surveillance are important
for follow up of infection and antibiotic resistance rates. In
line with these data, strategies for prevention of infections
can be developed and empirical treatment protocols can
be prepared.
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